Expert insights. Personalized for you.
The FDA approved 309 new drugs between 2011 and 2018, 38 per year on average. In 2018, the FDA approved 59 new drugs – an all-time high. The industry loses an average of $40 billion per year on drug development, part of which is due to trial delays. MORE
A new deal with Sosei Heptares hands Neurocrine a "broad portfolio" of drugs for schizophrenia, dementia and other neuropsychiatric disorders MORE
Biogen, along with allies in industry, plans to pressure Medicare to water down its policy, which limits coverage of Aduhelm and drugs like it to clinical trials MORE
This translates to longer development times for cancer drugs which means that cancer patients could suffer. It’s essential that drug companies get creative and find new ways to reach patients when incomes to cancer drug screening and clinical trials. MORE
SUMMARY: Democratic lawmakers are weighing whether to include drug pricing measures that could extract tens of billions of dollars from the industry. We’re just not sure when,” said one drug industry lobbying source. The drug industry has had a large target on its back for a long time. MORE
Detailed results presented Thursday show no difference between the biotech's drug and placebo on the study's main measures. But a seeming benefit in a subgroup of patients convinced the company to plan another trial MORE
SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. ” For Biogen, the stakes are high as approval is likely to earn tens of millions, of to billions, in profits but is hope a reason to approve a drug over science? MORE
With other COVID treatments ineffective against the variant or in short supply, the FDA is expanding its approval of Veklury to include outpatient use MORE
According to the drugmaker, the FDA asked in a complete response letter for more information related to how the drug's efficacy was measured MORE
Chemistry AND Physics Drugs heavy hydrogen stabilizesHydrogen (abbreviated “H”) is the lightest of all elements. It usually consists only of a positively charged proton and a negatively charged electron and is also called protium in this form. MORE
The acquisition reflects growing industry interest in the cancer-linked protein targeted by Trillium's drugs, most notably shown by Gilead's acquisition of Forty Seven last year MORE
SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Drug Prices MORE
Gilead Sciences has been seizing counterfeit versions of its HIV drugs Biktarvy and Descovy since last year and is now suing distributors who have been behind selling the illicit medications. The counterfeit drugs were being sold across several states in the US over the past two years. MORE
SUMMARY: Large-cap pharma companies are trading higher in the morning hours after White House unveiled a framework for a deal on President Biden’s social spending package on Thursday leaving out a key provision that allowed Medicare to negotiate lower prescription drug prices. MORE
Independent teams from Texas Biomedical Research Institute and the Medical College of Wisconsin have published two papers in Science Translational Medicine identifying how the only approved drug to treat schistosomiasis, a widespread parasitic worm infection, works on the molecular level. MORE
After halting a Phase 3 trial of the drug last year, Roche went digging for more data. What it found led to plans for another trial, but the pharma's hypothesis may rest on shaky ground MORE
Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019 MORE
Powerful associates of Syria’s president, Bashar al-Assad, are making and selling captagon, an illegal amphetamine, creating a new narcostate on the Mediterranean. MORE
based Immunocore's treatment, known as Kimmtrak, is also the first T cell receptor drug to have reached market in the U.S. so far MORE
But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. MORE
The biotech said it plans to soon submit the drug, which it acquired for cheap from Gilead three years ago, to the Food and Drug Administration for approval MORE
Neurimmune, which will license to AstraZeneca an early-stage treatment for a rare form of cardiomyopathy, is probably best known for its invention of the antibody that became Biogen's Alzheimer's drug Aduhelm MORE
A European Medicines Agency panel tasked with reviewing drugs voted against the biotech's controversial Alzheimer's medicine, signaling an approval is unlikely next month MORE
AstraZeneca aims to help the biotech make a drug based on its findings After screening 650,000 people, Regeneron unearthed a mutation associated with lower weight. MORE
Sunovion will receive $270 million from Otsuka, and as much as $620 million more, in exchange for splitting rights to four experimental psychiatric drugs MORE
This includes about one in five who report that they have not filled a prescription or took an over-the counter drug instead, and about one in ten who say they have cut pills in half or skipped a dose. Drug prices in the United States are extreme. Drug Prices MORE
Ten months after Roche stopped giving the drug to patients in a Phase 3 trial, the pharma is planning a new study on the belief the medicine may help younger adult patients with less advanced disease MORE
AbbVie's Rinvoq and Pfizer's Cibinqo are both JAK-inhibiting drugs that are taken orally, a convenience which could help them compete against injectable treatments like Sanofi and Regeneron's Dupixent MORE
Lumakras is the first drug proven effective For decades, scientists have tried unsuccessfully to target the KRAS gene, which is often mutated in lung, colon and pancreatic cancers. MORE
Study results for Mirati's drug combined with Keytruda have been much anticipated, as the San Diego biotech aims to challenge Amgen and its rival KRAS-blocking drug Lumakras MORE
It’s being positioned as an anti-obesity drug, but one study by Novo Nordisk has shown that people who stop taking Wegovy after a few months tend to regain much of their lost weight within a year. The post <i>“Game-changing”</i> obesity drug over-promising? MORE
Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more MORE
A topical cream formulation of the drug in Incyte's top-selling product could help the company expand. The black box warning, though, might limit use MORE
Yet the media has led with “diabetes drug leads to major weight loss” Will doctors inform patients? The drug carries a potential risk for a type of thyroid tumor and has a boxed warning. This drug can be effective if patients follow the directions for weight loss. MORE
While it’s true, the drug industry developed COVID vaccines; the government spent billions on research pre-pandemic and $18 billion more on trials, production, and purchase. Drug corps are reaping record profits. Drug companies should prepare for this scenario. MORE
New research suggests manufacturers of newly developed antidepressant drugs have become more forthcoming about clinical trials that don’t pan out. Latest News antidepressant Drug Improved reports review Transparency trials MORE
Biopharmaceutical companies have ongoing and extensive needs for print and digital communications throughout the drug development life cycle that can benefit from a single-source vendor MORE
SUMMARY: The new, proposed, drug legislation is a first step rather than a sweeping change. It’s a collection of measures meant to bring down prices slowly and on targeted drugs, and pharma is already complaining. The post New legislation is a great first step to lower drug prices. MORE
Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. Latest News clinical Drug Limitations research MORE
SUMMARY: The FDA has many puzzled as to why they approve some drugs with questionable data and ask for more data on other drugs. The FDA approves drugs on the potential to save a life, the cost of the drugs is never considered in the process. MORE
The pharmaceutical giant is spending $80 million for an exclusive license to an experimental drug developed by Prothena MORE
Study results show EQRx's drug, which it means to position as a lower-cost alternative to widely used cancer immunotherapies, extended the lives of lung cancer patients. MORE
Open source drug discovery was proposed in the past in connection with third-world diseases like tuberculosis and malaria, but it is in the context of first-world indications where it is needed most. The post Open Source “Wikipedia” for Drug Discovery appeared first on Pharma Mirror Magazine. MORE
According to the KFF poll “ most adults – across partisans – don’t believe high drug prices are needed for drug companies to invest in new research instead agreeing that “even if U.S. The post Pharma losing the battle over drug prices. MORE
Drugs Related Topics World of DTC Marketing
OCTOBER 12, 2021
According to the KFF poll “ most adults – across partisans – don’t believe high drug prices are needed for drug companies to invest in new research instead agreeing that “even if U.S. The post Pharma losing the battle over drug prices.
World of DTC Marketing
SEPTEMBER 7, 2021
While it’s true, the drug industry developed COVID vaccines; the government spent billions on research pre-pandemic and $18 billion more on trials, production, and purchase. Drug corps are reaping record profits. Drug companies should prepare for this scenario.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JULY 13, 2021
SUMMARY: The FDA has many puzzled as to why they approve some drugs with questionable data and ask for more data on other drugs. The FDA approves drugs on the potential to save a life, the cost of the drugs is never considered in the process.
Bio Pharma Dive
JANUARY 24, 2022
According to the drugmaker, the FDA asked in a complete response letter for more information related to how the drug's efficacy was measured
Bio Pharma Dive
JANUARY 18, 2022
Ten months after Roche stopped giving the drug to patients in a Phase 3 trial, the pharma is planning a new study on the belief the medicine may help younger adult patients with less advanced disease
World of DTC Marketing
DECEMBER 10, 2020
SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Drug Prices
World of DTC Marketing
JUNE 16, 2021
This includes about one in five who report that they have not filled a prescription or took an over-the counter drug instead, and about one in ten who say they have cut pills in half or skipped a dose. Drug prices in the United States are extreme. Drug Prices
World of DTC Marketing
MARCH 23, 2021
SUMMARY: Democratic lawmakers are weighing whether to include drug pricing measures that could extract tens of billions of dollars from the industry. We’re just not sure when,” said one drug industry lobbying source. The drug industry has had a large target on its back for a long time.
Bio Pharma Dive
JANUARY 11, 2022
Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more
Bio Pharma Dive
JANUARY 7, 2022
Neurimmune, which will license to AstraZeneca an early-stage treatment for a rare form of cardiomyopathy, is probably best known for its invention of the antibody that became Biogen's Alzheimer's drug Aduhelm
World of DTC Marketing
OCTOBER 6, 2020
This translates to longer development times for cancer drugs which means that cancer patients could suffer. It’s essential that drug companies get creative and find new ways to reach patients when incomes to cancer drug screening and clinical trials.
Scienmag
DECEMBER 23, 2021
Chemistry AND Physics Drugs heavy hydrogen stabilizesHydrogen (abbreviated “H”) is the lightest of all elements. It usually consists only of a positively charged proton and a negatively charged electron and is also called protium in this form.
Bio Pharma Dive
JANUARY 21, 2022
After halting a Phase 3 trial of the drug last year, Roche went digging for more data. What it found led to plans for another trial, but the pharma's hypothesis may rest on shaky ground
|
Bio Pharma Dive
NOVEMBER 22, 2021
A new deal with Sosei Heptares hands Neurocrine a "broad portfolio" of drugs for schizophrenia, dementia and other neuropsychiatric disorders
World of DTC Marketing
NOVEMBER 3, 2021
SUMMARY: The new, proposed, drug legislation is a first step rather than a sweeping change. It’s a collection of measures meant to bring down prices slowly and on targeted drugs, and pharma is already complaining. The post New legislation is a great first step to lower drug prices.
Bio Pharma Dive
NOVEMBER 17, 2021
A European Medicines Agency panel tasked with reviewing drugs voted against the biotech's controversial Alzheimer's medicine, signaling an approval is unlikely next month
Bio Pharma Dive
SEPTEMBER 21, 2021
Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019
World of DTC Marketing
JUNE 27, 2021
Yet the media has led with “diabetes drug leads to major weight loss” Will doctors inform patients? The drug carries a potential risk for a type of thyroid tumor and has a boxed warning. This drug can be effective if patients follow the directions for weight loss.
World of DTC Marketing
NOVEMBER 5, 2021
It’s being positioned as an anti-obesity drug, but one study by Novo Nordisk has shown that people who stop taking Wegovy after a few months tend to regain much of their lost weight within a year. The post <i>“Game-changing”</i> obesity drug over-promising?
Bio Pharma Dive
JANUARY 14, 2022
Biogen, along with allies in industry, plans to pressure Medicare to water down its policy, which limits coverage of Aduhelm and drugs like it to clinical trials
Pharma Mirror
OCTOBER 4, 2021
Open source drug discovery was proposed in the past in connection with third-world diseases like tuberculosis and malaria, but it is in the context of first-world indications where it is needed most. The post Open Source “Wikipedia” for Drug Discovery appeared first on Pharma Mirror Magazine.
Scienmag
JANUARY 19, 2022
New research suggests manufacturers of newly developed antidepressant drugs have become more forthcoming about clinical trials that don’t pan out. Latest News antidepressant Drug Improved reports review Transparency trials
Bio Pharma Dive
DECEMBER 20, 2021
Biopharmaceutical companies have ongoing and extensive needs for print and digital communications throughout the drug development life cycle that can benefit from a single-source vendor
Bio Pharma Dive
NOVEMBER 12, 2021
Detailed results presented Thursday show no difference between the biotech's drug and placebo on the study's main measures. But a seeming benefit in a subgroup of patients convinced the company to plan another trial
Bio Pharma Dive
JANUARY 26, 2022
based Immunocore's treatment, known as Kimmtrak, is also the first T cell receptor drug to have reached market in the U.S. so far
Bio Pharma Dive
JANUARY 18, 2022
AbbVie's Rinvoq and Pfizer's Cibinqo are both JAK-inhibiting drugs that are taken orally, a convenience which could help them compete against injectable treatments like Sanofi and Regeneron's Dupixent
Bio Pharma Dive
NOVEMBER 8, 2021
Study results for Mirati's drug combined with Keytruda have been much anticipated, as the San Diego biotech aims to challenge Amgen and its rival KRAS-blocking drug Lumakras
Bio Pharma Dive
JUNE 24, 2021
The pharmaceutical giant is spending $80 million for an exclusive license to an experimental drug developed by Prothena
Bio Pharma Dive
JANUARY 19, 2022
Study results show EQRx's drug, which it means to position as a lower-cost alternative to widely used cancer immunotherapies, extended the lives of lung cancer patients.
Bio Pharma Dive
AUGUST 23, 2021
The acquisition reflects growing industry interest in the cancer-linked protein targeted by Trillium's drugs, most notably shown by Gilead's acquisition of Forty Seven last year
World of DTC Marketing
OCTOBER 28, 2021
SUMMARY: Large-cap pharma companies are trading higher in the morning hours after White House unveiled a framework for a deal on President Biden’s social spending package on Thursday leaving out a key provision that allowed Medicare to negotiate lower prescription drug prices.
XTalks
JANUARY 24, 2022
Gilead Sciences has been seizing counterfeit versions of its HIV drugs Biktarvy and Descovy since last year and is now suing distributors who have been behind selling the illicit medications. The counterfeit drugs were being sold across several states in the US over the past two years.
Bio Pharma Dive
MAY 28, 2021
Lumakras is the first drug proven effective For decades, scientists have tried unsuccessfully to target the KRAS gene, which is often mutated in lung, colon and pancreatic cancers.
Bio Pharma Dive
DECEMBER 22, 2021
But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations.
World of DTC Marketing
JUNE 1, 2021
SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. ” For Biogen, the stakes are high as approval is likely to earn tens of millions, of to billions, in profits but is hope a reason to approve a drug over science?
Bio Pharma Dive
SEPTEMBER 22, 2021
A topical cream formulation of the drug in Incyte's top-selling product could help the company expand. The black box warning, though, might limit use
NY Times
DECEMBER 5, 2021
Powerful associates of Syria’s president, Bashar al-Assad, are making and selling captagon, an illegal amphetamine, creating a new narcostate on the Mediterranean.
Bio Pharma Dive
JANUARY 25, 2022
The biotech said it plans to soon submit the drug, which it acquired for cheap from Gilead three years ago, to the Food and Drug Administration for approval
Bio Pharma Dive
SEPTEMBER 30, 2021
Sunovion will receive $270 million from Otsuka, and as much as $620 million more, in exchange for splitting rights to four experimental psychiatric drugs
Scienmag
DECEMBER 28, 2021
Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. Latest News clinical Drug Limitations research
Scienmag
JANUARY 6, 2022
Independent teams from Texas Biomedical Research Institute and the Medical College of Wisconsin have published two papers in Science Translational Medicine identifying how the only approved drug to treat schistosomiasis, a widespread parasitic worm infection, works on the molecular level.
Bio Pharma Dive
JANUARY 24, 2022
With other COVID treatments ineffective against the variant or in short supply, the FDA is expanding its approval of Veklury to include outpatient use
Bio Pharma Dive
JULY 27, 2021
AstraZeneca aims to help the biotech make a drug based on its findings After screening 650,000 people, Regeneron unearthed a mutation associated with lower weight.
161 
Let's personalize your content